Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229


Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

Drug Alcohol Depend. 2013 Dec 1;133(2):376-82. doi: 10.1016/j.drugalcdep.2013.06.024. Epub 2013 Jul 31.


Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.

Piralishvili G, Otiashvili D, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

J Subst Abuse Treat. 2015 Mar;50:32-7. doi: 10.1016/j.jsat.2014.10.003. Epub 2014 Oct 22.


Evaluation of state opioid substitution treatment program in Georgia.

Piralishvili G, Chavchanidze M, Gamkrelidze I, Nikolaishvili N.

Georgian Med News. 2014 Apr;(229):62-6.


The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.

Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O'Connor PG, Weiss L, Fiellin DA, Fiellin LE.

Drug Alcohol Depend. 2014 Jun 1;139:79-85. doi: 10.1016/j.drugalcdep.2014.03.006. Epub 2014 Mar 15.


Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.


Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA; BHIVES Collaborative..

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S14-21. doi: 10.1097/QAI.0b013e318209d3b9.


Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W.

J Stud Alcohol Drugs. 2013 Jul;74(4):605-13.


Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.

Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL.

Drug Alcohol Depend. 2003 Apr 1;69(3):263-72.


HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.

Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, Jacobs P, Sorensen J, Saxon AJ, Metzger D, Ling W.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):288-93. doi: 10.1097/QAI.0000000000000165.


Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W.

Addiction. 2016 Apr;111(4):695-705. doi: 10.1111/add.13238. Epub 2016 Jan 13.


Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.


Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.

Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.


Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.

Tsui JI, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Mao J, Edwards RR, Samet JH.

Drug Alcohol Depend. 2015 Aug 1;153:286-92. doi: 10.1016/j.drugalcdep.2015.05.011. Epub 2015 May 22.


Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.

Vijay A, Bazazi AR, Yee I, Kamarulzaman A, Altice FL.

J Subst Abuse Treat. 2015 Jul;54:29-36. doi: 10.1016/j.jsat.2015.01.014. Epub 2015 Feb 18.


HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.

Lott DC, Strain EC, Brooner RK, Bigelow GE, Johnson RE.

J Subst Abuse Treat. 2006 Sep;31(2):187-94. Epub 2006 Jul 18. Erratum in: J Subst Abuse Treat. 2006 Oct;31(3):317.


Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care.

Otiashvili D, Kirtadze I, O'Grady KE, Jones HE.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):14-21. doi: 10.1016/j.drugalcdep.2011.06.012. Epub 2011 Jul 13.


Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.

Curcio F, Franco T, Topa M, Baldassarre C; Gruppo Responsabili UO Sert T..

Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):871-4.


Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.

Maas J, Barton G, Maskrey V, Pinto H, Holland R.

Drug Alcohol Depend. 2013 Dec 1;133(2):494-501. doi: 10.1016/j.drugalcdep.2013.07.018. Epub 2013 Aug 17.


Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.

Springer SA, Chen S, Altice FL.

J Urban Health. 2010 Jul;87(4):592-602. doi: 10.1007/s11524-010-9438-4.


Use and misuse of opioid replacement therapies: a Queensland study.

Smirnov A, Kemp R.

Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.


Supplemental Content

Support Center